When treatment of rheumatic diseases with adalimumab fails, a physician may need to consider treatment options, such as adjusting dose or dosing intervals, switching to a different TNF blocker, or switching to a different drug agent, i.e. a non-TNF blocker. This assay specifically detects antibodies to adalimumab that may reduce serum levels of the drug, as well as its clinical efficacy.
Patient Preparation: No biotin supplements 48 hours prior to blood
draw. Fasting not required
Reported (Analytical Time)
The CPT codes provided are based on AMA guidelines and are for informational purposes only.
CPT coding is the sole responsibility of the billing party.
Please direct any questions regarding coding to the payer being billed.
**This test is not available for New York patient testing** Reject Criteria: Serum Separator Tube Transport Temperature: Refrigerated Specimen Stability: Frozen (-20 degrees Celsius): 14 days Frozen (-70 degrees Celsius): 60 days Methodology: Enzyme Linked Immunosorbent Assay